274671-76-0

Upstream product

• 7149-69-1 1,3-dichloro-2-methyl-5-nitrobenzene 
• 54730-35-7 3,5-dichloro-4-methylaniline 
• 204930-37-0 4-bromo-2,6-dichlorotoluene 

Downstream Products

• 956123-16-3 2-(4-bromo-2,6-dichloro-benzyl)-2-aza-spiro[4.5]decan-1-one 
• 956319-67-8 1-(4-bromo-2,6-dichloro-benzyl)-3-piperidin-1-yl-pyrrolidin-2-one 
• 111829-72-2 4-bromo-2,6-dichlorobenzaldehyde 
• 274671-77-1 4-bromo-2,6-dichlorobenzyl alcohol 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity.

INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: having 11 Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11Beta-HSD type 1 activity. X-17377

Kinetic studies on the interactions of manganese-porphyrins with peracetic acid. Part 1. Epoxidation of alkenes and hydroxylation of aromatic rings

The mechanism of peracetic acid interactions with MnIII complexes of meso-tetra(2,6-dichloro-4-R-phenyl)-porphyrins (RTDCPPMnCl; R = CH3O, H, Br, Cl or NO2) in acetonitrile-acetic acid has been studied. Analysis of the kinetic data revealed that both in cis-stilbene epoxidation and naphthalene hydroxylation the first step of the reaction is the reversible formation of an intermediate adduct 'A' between the catalyst and the oxidant. The subsequent irreversible transformation of 'A' with rate constant k2 leads to the formation of two high-valent oxometallo species, [RTDCPPMnV(O)] and supposedly [RTDCPPMnIV(O)]+. These species are in equilibrium and show distinct oxidation abilities towards the substrates.